BR112022023669A2 - Vlp para o tratamento de leucodistrofias - Google Patents

Vlp para o tratamento de leucodistrofias

Info

Publication number
BR112022023669A2
BR112022023669A2 BR112022023669A BR112022023669A BR112022023669A2 BR 112022023669 A2 BR112022023669 A2 BR 112022023669A2 BR 112022023669 A BR112022023669 A BR 112022023669A BR 112022023669 A BR112022023669 A BR 112022023669A BR 112022023669 A2 BR112022023669 A2 BR 112022023669A2
Authority
BR
Brazil
Prior art keywords
enzyme
leukodystrophies
vlp
treatment
expression vector
Prior art date
Application number
BR112022023669A
Other languages
English (en)
Inventor
Demina Victoria
Ernst Oliver
Hermann Anke
Stapf Markus
Original Assignee
Neuway Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuway Pharma Gmbh filed Critical Neuway Pharma Gmbh
Publication of BR112022023669A2 publication Critical patent/BR112022023669A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01015—Aspartoacylase (3.5.1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/22042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

VLP PARA O TRATAMENTO DE LEUCODISTROFIAS. A presente invenção refere-se a partículas semelhantes a vírus (VLP) associadas a uma enzima expressa anormalmente em leucodistrofias particulares ou um vetor de expressão que codifica a enzima ou um mRNA que codifica a enzima ou uma combinação dos mesmos que são usados em um método para o tratamento de leucodistrofias específicas em um indivíduo que precisa do mesmo, de preferência um ser humano. A invenção refere-se também a uma composição farmacêutica para uso em um método para o tratamento de leucodistrofias particulares, a um vetor de expressão que codifica a enzima expressa anormalmente e a um método de associação de uma VLP com a enzima, um vetor de expressão que codifica a enzima ou um mRNA que codifica a enzima ou uma combinação dos mesmos.
BR112022023669A 2020-05-22 2021-05-19 Vlp para o tratamento de leucodistrofias BR112022023669A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2020064324 2020-05-22
PCT/EP2021/063375 WO2021234046A1 (en) 2020-05-22 2021-05-19 Vlp for the treatment of leukodystrophies

Publications (1)

Publication Number Publication Date
BR112022023669A2 true BR112022023669A2 (pt) 2023-01-31

Family

ID=71096660

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023669A BR112022023669A2 (pt) 2020-05-22 2021-05-19 Vlp para o tratamento de leucodistrofias

Country Status (7)

Country Link
US (1) US20230310652A1 (pt)
EP (1) EP4153756A1 (pt)
JP (1) JP2023526528A (pt)
CN (1) CN115968403A (pt)
BR (1) BR112022023669A2 (pt)
CA (1) CA3184307A1 (pt)
WO (1) WO2021234046A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19543553B4 (de) 1995-11-22 2009-04-09 Deutsches Primatenzentrum Gmbh VP-Antigene des JC-Virus
WO2008134123A1 (en) * 2007-04-30 2008-11-06 The Uab Research Foundation Ul97 for treatment of protein aggregate disorders
FR2920158B1 (fr) 2007-08-24 2010-03-12 Centre Nat Rech Scient Production de plasmides et expression de proteines recombinantes dans des cellules cultivees sans antibiotiques
ME02606B (me) 2012-06-15 2017-06-20 Taisho Pharmaceutical Co Ltd Jedinjenja 1,3 - oksazolidina ili 1,3- oksazinana kao antagonisti oreksinskog receptora
EP2882284B1 (en) 2012-08-07 2017-11-15 Chiesi Farmaceutici S.p.A. Animal model of krabbe's disease
AU2019227896A1 (en) * 2018-02-28 2020-08-20 The University Of North Carolina At Chapel Hill Methods and compositions for antibody-evading virus vectors
BR112019014209A2 (pt) * 2018-12-18 2021-09-28 Neuway Pharma Gmbh Sistema de liberação de fármaco, método para provimento do mesmo, partículas semelhantes a vírus (vlp), composição e uso do sistema de liberação de fármaco

Also Published As

Publication number Publication date
CA3184307A1 (en) 2021-11-25
WO2021234046A1 (en) 2021-11-25
CN115968403A (zh) 2023-04-14
US20230310652A1 (en) 2023-10-05
JP2023526528A (ja) 2023-06-21
EP4153756A1 (en) 2023-03-29

Similar Documents

Publication Publication Date Title
MX2022009460A (es) Vacuna contra el coronavirus.
MX2023007574A (es) "vacuna de arn contra variantes de sars-cov-2.
SG10201902664RA (en) Combination therapy for treating cancer
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
BR112022005687A2 (pt) Vacinas contra o hbv e métodos para tratar o hbv
BR112021015751A2 (pt) Vetores de terapia genética para tratamento da doença de danon
BR112021019262A2 (pt) Uso de ciclo-his-pro (chp) para prevenir, atenuar ou tratar fibrose
BR112018074152A8 (pt) Métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico
WO2018208793A8 (en) S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY
BR112014023572A2 (pt) método para tratar ou prevenir dano de articulação em um indivíduo com ra precoce ou ra incipiente, uso de um agente ou combinação de agentes que estimulam uma resposta tolerogênica específica de antígeno a um polipeptídeo de agrecan, e agente ou combinação de agentes
BR112022024404A2 (pt) Método para tratar câncer, sequência de nucleotídeos, célula hospedeira, partícula de lcmv, partícula de picv, composição farmacêutica, partícula de arenavírus
ZA202106769B (en) Treatment of ciliopathies
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
AR112166A1 (es) Composiciones terapéuticas y métodos para el tratamiento de hepatitis b
BR112022013646A2 (pt) Método de tratamento de esplenomegalia
MX2022012925A (es) Composición de vacuna contra la peste porcina africana.
MX2021004207A (es) Uso de reboxetina para el tratamiento de narcolepsia.
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
BR112022023669A2 (pt) Vlp para o tratamento de leucodistrofias
BR112022019137A2 (pt) Composições e métodos de tratamento de distrofia muscular
BR112021023319A2 (pt) Vetor viral
BR112022010750A2 (pt) Método para tratar câncer usando célula adjuvante artificial (aavc)
BR112022012081A2 (pt) Método para tratar câncer, kit, e, uso de uma combinação terapêutica
BR112022011388A2 (pt) Métodos para tratar ou prevenir asma alérgica administrando um antagonista de il-33 e/ou um antagonista de il-4r
BR112021024644A2 (pt) Composições de lactobacillus e usos das mesmas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing